Sex-specific differences in hepatic steatosis in obese spontaneously hypertensive (SHROB) rats

Qingming Dong 1,2, Michael S. Kuefner 1,2, Xiong Deng 1,2, Dave Bridges 3, Edwards A. Park 1,2, Marshall B. Elam 1,2,4, and Rajendra Raghow 1,2,4*

Abstract

Background: Patients with metabolic syndrome, who are characterized by co-existence of insulin resistance, hypertension, hyperlipidemia, and obesity, are also prone to develop non-alcoholic fatty liver disease (NAFLD). Although the prevalence and severity of NAFLD is significantly greater in men than women, the mechanisms by which gender modulates the pathogenesis of hepatic steatosis are poorly defined. The obese spontaneously hypertensive (SHROB) rats represent an attractive model of metabolic syndrome without overt type 2 diabetes. Although pathological manifestation caused by the absence of a functional leptin receptor has been extensively studied in SHROB rats, it is unknown whether these animals elicited sex-specific differences in the development of hepatic steatosis.

Methods: We compared hepatic pathology in male and female SHROB rats. Additionally, we examined key biochemical and molecular parameters of signaling pathways linked with hyperinsulinemia and hyperlipidemia. Finally, using methods of quantitative polymerase chain reaction (qPCR) and western blot analysis, we quantified expression of 45 genes related to lipid biosynthesis and metabolism in the livers of male and female SHROB rats.

Results: We show that all SHROB rats developed hepatic steatosis that was accompanied by enhanced expression of SREBP1, SREBP2, ACC1, and FASN proteins. The livers of male rats also elicited higher induction of Pparg, Ppara, Slc2a4, Atox1, Skp1, Angptl3, and Pnpla3 mRNAs. In contrast, the livers of female SHROB rats elicited constitutively higher levels of phosphorylated JNK and AMPK and enhanced expression of Cd36.

Conclusion: Based on these data, we conclude that the severity of hepatic steatosis in male and female SHROB rats was mainly driven by increased de novo lipogenesis. Moreover, male and female SHROB rats also elicited differential severity of hepatic steatosis that was coupled with sex-specific differences in fatty acid transport and esterification.

Background

Metabolic syndrome (MetS), a sequela characterized by the co-occurrence of insulin resistance, hypertension, hyperlipidemia, and obesity [1], is emerging as a major public health challenge, affecting nearly one third of adults in the USA of America [2]. Epidemiological studies have clearly demonstrated that although both genetic and environmental factors underlie the development of MetS, its primary drivers are overconsumption of calorie-dense foods and sedentary lifestyle. Clinical correlates of MetS and its molecular underpinnings have been extensively investigated in rodent models such as ob/ob mice [3], db/db mice [4], and fa/fa rats [5]. Although it is well known that rodent models of MetS mimic the human syndrome to varying degrees [6], studies in rodents have yielded critical evidence that mechanistically links hallmarks of MetS (visceral adiposity, hyperglycemia, and hypertension), with mechanisms of nutrient partitioning and energy homeostasis. Experimental animals have also played a crucial role in unraveling the genetic, neuronal, and humeral mechanisms involved in the control of food intake and...
energy metabolism and how their defective regulation leads to MetS [7–10].

The obese spontaneously hypertensive (SHROB) rats, also known as Koletsky rats, are thought to manifest the essential traits that characterize the MetS [11]. The SHROB rats were shown to be unique since they not only elicited genetic hypertension similar to their lean, spontaneously hypertensive (SHR) parents but also elicited congenital obesity on regular chow diet. The genome of SHROB rat harbors a nonsense mutation in codon 763 of the gene encoding the leptin receptor [12]. SHROB rats express normal amounts of mutated leptin receptor messenger RNA that fails to be translated into functional leptin. The gene encoding the leptin receptor was shown to be hyper-secretory in their bloodstream. Thus, besides being hypertensive, SHROB rats elicited monogenic obesity that was associated with hyperlipidemia, hyperinsulinemia, and striking proteinuria and renal disease [11]. It is also noteworthy however, that although SHROB rats were glucose intolerant compared with their heterozygous or WT littermates, their fasting glucose levels were normal even on a high-sucrose diet. Strikingly, both male and female SHROB rats were infertile and had a shorter lifespan, surviving only for 10–11 months while their WT littermates had an average lifespan of 2–3 years [16, 17].

The prevalence and severity of non-alcoholic fatty liver disease (NAFLD) in many populations around the globe is higher in men than women [18–20]. Although some gender-specific differences in the metabolism of dietary glucose and fatty acids in humans have been reported [21], how they differentially modulate the pathogenesis of hepatic steatosis and NAFLD is far from clear [22]. SHROB rats are known to develop hepatomegaly and fatty liver similar to many patients with MetS. Several investigators have peered into the hormonal and biochemical underpinnings of adiposity and MetS in SHROB rats [23–25]. For instance, Ernsberger et al. observed widespread deposition of fat in the SHROB rats but noted that their retroperitoneal and subscapular adipose depots were particularly prominent [26]. These authors also reported that, in contrast to their SHR counterparts, the adiposity of SHROB rats was apparently affected by their sex; they showed that while SHROB males accumulated nearly 12-fold higher amount of epididymal fat, the myometrial fat depots in female SHROB rats were elevated by 19-fold. Based on the rates of incorporation of labeled glucose into lipids in various tissues (e.g., muscle, adipose tissue, and liver), Ernsberger et al. surmised that obesity of SHROB rats was mainly driven by de novo lipid synthesis [26]. Although these observations hinted at the possibility of sexual dimorphism underlying the development of MetS, its putative sex-specific consequences on the metabolism of lipids in the liver of SHROB rats were not studied in depth. To address this question, we examined the signaling pathways canonically linked with hyperinsulinemia in the livers of male and female SHROB rats. Additionally, we compared the expression of a set of 45 candidate genes that are known to be involved in sex-specific regulation of the biosynthesis and metabolism of lipids. Our findings corroborate and extend previous studies to indicate that hepatic steatosis and its molecular mechanisms are indeed differentially regulated in male and female SHROB rats.

Methods

Reagents

Anti-IRS-1, anti-pIRS-1 (S307), anti-AKT (T308), anti-AKT, anti-p-mTOR (S2448), anti-mTOR, anti-p-p70S6K (T389), anti-p-p70S6K, anti-p-p70S6K, anti-p-pS6K (S235/S236), anti-S6, anti-p-p38MAPK (T180/Y182), anti-p38MAPK, anti-p-ERK1/2 (T202/Y204), anti-ERK1/2, anti-p-SAPK/JNK (T183/Y185), anti-SAPK/JNK, anti-p-AMPK (T172), anti-AMPK, anti-ACC1, and anti-FASN monospecific antibodies were purchased from Cell Signaling (Danvers, MA). Insulin, Oil Red O, and anti-actin antibodies were obtained from Sigma-Aldrich (St. Louis, MO). Anti-SREBP2 antibody was bought from Becton-Dickinson (Franklin Lakes, NJ). Anti-SREBP1 antibody was bought from Research Diets Inc. (New Brunswick, NJ). Combined protease and phosphatase inhibitor cocktails (Halt”) and Tissue-Tek™ optimum cutting temperature (OCT) compound were bought from Thermo Fisher Scientific (Hampton, NH). Forward and reverse oligonucleotide primers (Additional file 1: Table S1) to carry out quantitative PCR analysis were designed according to a published program (OligoArchitect™ online, Sigma-Aldrich, St. Louis, MO). DNA primers were synthesized by Integrated DNA Technologies (Coralville, IA).

Animal husbandry, genotyping, and laboratory studies

All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of University of Tennessee Health Science Center (UTHSC), Memphis. Adult male and female heterozygous SHROB breeding pairs were obtained from a closed colony that has been continuously maintained since 1973 [26]. Since homozygous rats are sterile, the SHROB strain was propagated by mating age-matched heterozygous males and females. Rats were housed in a room with a constant light and dark cycle of 12–12 h, at 20–23 °C. Animals had full access to Teklad LM-485 mouse/rat chow (containing 17, 25, and 58% calories from fat, protein, and carbohydrate, respectively), bought from Research Diets Inc. (New Brunswick, NJ). Most experimental measurements, signal transduction, and gene expression analyses (western blot and qPCR) were carried out on 10-week-old homozygous male and female SHROB rats.
Tail clip DNA samples, extracted using DNase Blood & Tissue Kit (Qiagen, Hilden, Germany), were subject to PCR with tetra-pair ARMS (amplification-refractory mutation system) primers (Additional file 1: Table S1) that were designed as described in detail (http://primer1.soton.ac.uk/primer1.html). The PCR was done using Thermo Scientific DreamTaq PCR Master Mix (2×) in a SimpliAmp Thermal Cycler (Applied Biosystems by Life Technologies, Foster City, CA). The PCR conditions were 94°C for 3 min, 35 cycles of 94°C 1 min, 51.1°C 1 min, and 72°C 1 min, followed by extension at 72°C for 10 min. DNA fragments containing codon 763 of the leptin receptor gene were amplified with two outer primers (Additional file 1: Figure S1a and b) and purified by ExoSAP-IT™ PCR Product Cleanup Reagent from Thermo Fisher Scientific (Waltham, MA). Amplified genomic DNA fragments were sequenced in the Molecular Resource Center of the UTHSC, using ABI Model 3130XL Genetic Analyzers (Foster City, CA) with four-color fluorescence-based sequencing.

Body weight was measured weekly between weeks 3 and 10. Total fat mass and fat-free mass of WT and homozygous SHROB rats were measured at week 10, using a magnetic resonance imaging (MRI) machine, EchoMRI-1100 (EchoMRI LLC, Houston, TX). Blood was collected from 10-week-old rats via cardiac puncture, and serum was obtained from clotted blood. Concentrations of alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine, cholesterol, glucose, and triglyceride in the sera were determined by IDEXX BioResearch Laboratories (Columbia, MO).

Western blot analysis
Protein extracts from homogenized livers were size-fractionated by SDS-PAGE and transferred onto nitrocellulose membranes that were probed with monospecific, primary, and secondary antibodies as described previously in detail [27]. Western blots were quantified using Quantity One software from Bio-Rad (Hercules, CA).

Quantification of gene expression by qPCR
Three replicate liver samples, representing WT and SHROB male and female rats, were used to extract total RNA using Trizol reagent (Invitrogen, Carlsbad, CA). RNA was converted into cDNA and subject to quantitative PCR (qPCR) with gene-specific primers (Additional file 1: Table S1) and GoTaq qPCR Master Mix (Promega, Madison, WI). PCR amplification was carried out using a LightCycler 480 Real-Time PCR system (Roche, Basel, Switzerland). The specificity of the qPCR amplification was verified by melting curve analysis. Data were analyzed using the ΔΔCT threshold cycle method. Target mRNAs were normalized against Rn18s ribosomal RNA and fold changes in experimental samples relative to those in control samples were calculated [28].

Histology
Tissue samples fixed in 4% paraformaldehyde/PBS for 24 h and embedded in paraffin were cut into 5 μm sections. De-paraffinized liver sections were stained with hematoxylin and eosin (H&E). Blocks of fresh liver tissues were embedded in frozen OCT compound and cryo-sectioned into 14-μm-thick slices; tissue sections were stained with 0.3% Oil Red O for 5 min at room temperature to visualize intracellular accumulation of lipid droplets [29]. The Oil Red O staining of tissue sections was quantified using the ImageJ software (NIH, Bethesda, MD).

Extraction and measurement of triglyceride content in liver tissue
Measurements of hepatic TG content were done exactly as outlined in detail previously [30]. Fragments of frozen liver were taken up in homogenization buffer (50 mM Tris, pH 8, 5 mM EDTA, 30 mM mannitol, and cocktail of protease inhibitors) and lysed using a TissueLyser II (Qiagen). Total lipids were extracted with 250 mM KOH and a mixture of chloroform and methanol (2:1). Liver tissue extracts were centrifuged at 13,000 × g for 10 min. As described by Lu et al. [30], the bottom layer was dried and taken up in a mixture of 3 mL butanol, 1.66 mL Triton X-114, and 0.33 mL methanol, and TGs were quantified using the Sigma Triglyceride Assay Kit (Cat TR0100, Sigma-Aldrich).

Statistical analysis
Means ± SEM were derived from 3 to 5 experiments (as indicated in the figure legends). A two-way analysis of variance (ANOVA) was performed to assess statistically significant differences between groups, using GraphPad Prism 6.0 software (La Jolla, CA). p values of < 0.05 were considered to be statistically significant. Putative interactions between genotype and gender were similarly examined by two-way ANOVA measurements.

Results
Genotyping of SHROB rats
SHROB rats were genotyped using a strategy based on PCR amplification of genomic DNA followed by its sequencing (Additional file 1: Figure S1a and b). We designed four PCR primers to amplify a region of the leptin receptor genomic DNA that included T > A mutation that leads to premature termination of translation in the leptin receptor mRNA [13]. Amplification of the genomic DNA by PCR using flanking primers should yield a 248-bp DNA fragment regardless of the genotype whereas two internal primers should yield 184-bp and
118-bp fragments representing WT or SHROB alleles, respectively (Additional file 1: Figure S1a). As expected, genomic DNA of heterozygous rats produced three fragments, 248-bp, 184-bp, and 118-bp in length; in contrast, PCR amplification of homozygous SHROB genomic DNA produced 248-bp and 118-bp bands (data not shown). Sequencing of DNA around codon 763 of the leptin receptor gene unequivocally identified the genotypes of the WT, heterozygous, and homozygous rats (Additional file 1: Figure S1b).

**Gender-specific differences in body mass and liver size in SHROB rats**

We assessed rates of growth and body composition of female and male SHROB rats fed with a regular chow diet, between the ages of 3 and 10 weeks. As reported originally [11], the obese phenotype is recessive, and the gross morphology of heterozygous (Fa\(^{k}/fa^{k}\)) rats did not differ significantly from WT. Therefore, in our study, all comparisons were made either between WT and homozygous (fa\(^{k}/fa^{k}\)) SHROB rats or between SHROB (fa\(^{k}/fa^{k}\)) males and females. A representative WT and SHROB female and male rats at 10-week of age are shown in Fig. 1a. Body weights of 3-week-old rats, irrespective of their genotypes, were very similar. Additionally, although all animals steadily grew bigger over a period of 7 weeks, the growth curve of the SHROB male rats was the steepest among the four groups of animals; in contrast, WT females elicited the lowest rates of body mass gain (Fig. 1b). At week 10, males were visibly bigger than females (Fig. 1a–c).

Next, we measured relative changes in the total body fat and lean masses of WT and SHROB rats at week 10. Compared with WT rats, the fat mass of female and male SHROB rats was increased by 10.8- and 6.5-fold, respectively (Fig. 1d). Although, total fat mass of male SHROB rats was higher versus homozygous females (Fig. 1d), when expressed as percentage of body weight, fat mass increased to comparable levels in male and females (Fig. 1e). Moreover, although lean mass for both male WT and SHROB rats were higher than corresponding females, 10-week-old male SHROB rats lost significant lean mass compared to WT. In contrast, 10-week-old SHROB females gained lean mass compared with their WT female littermates (Fig. 1f). We should also note that at week 10, percent lean mass in both male and female SHROB rats was significantly decreased compared with WT rats, respectively (Fig. 1g). The results of two-way ANOVA (Figs. 2d–g) indicated that both genotype and gender contributed to age-dependent changes in fat mass, percent body fat, lean mass, and percent lean mass of SHROB rats fed a regular chow diet.

Visible gender-specific differences in the sizes of bodies of SHROB rats corresponded with the sizes of their livers (Fig. 2a, b). We also noted that although livers of both female and male SHROB rats grew bigger at week...
10, the livers of male rats were larger and paler in appearance (Fig. 2a). The apparent disparity in sizes of livers between male and female SHROB rats remained highly significant even after the normalization of their liver weights against body weights (Fig. 2c). These data revealed that, as expected, the livers of male SHROB rats were considerably larger than their male WT littermates. Even more significantly, the livers of male SHROB rats were even bigger and paler than those of SHROB females (Fig. 2a–c). To assess if gender-specific differences in gross morphology of male SHROB rats and their livers were related to putative changes in hepatic tissue architecture, we sectioned the livers from male and female SHROB rats and stained these with H&E and Oil Red O. As shown in Fig. 2e, H&E-stained sections of livers from male SHROB rats appeared highly vacuolated (denoting areas of lipid droplets accumulation, as judged by Oil Red O staining). Lipid-laden hepatocytes were more prevalent in the pericentral areas of the liver as opposed to periportal areas (Fig. 2e). Thus, Oil Red O staining revealed that although some hepatic steatosis was evident in all SHROB rats (unlike WT animals) regardless of their gender (Fig. 2f), SHROB males elicited more severe steatosis as judged by accumulation of lipid droplets (Fig. 2f). Quantification of lipid droplets confirmed the visual impression to reveal disproportionately greater accumulation of fat in the livers of male SHROB rats (Fig. 2g). We should note however, that in spite of the differences in the hepatic histology of male and female SHROB rats, H&E staining did not reveal signs of overt fibrosis (Fig. 2e; data not shown). However, these data led us to tentatively conclude that both genotype and gender contributed to the severity of hepatic steatosis in SHROB rats.
Biochemical analysis of serum in female and male SHROB rats
We analyzed the serum of male and female SHROB rats for markers of hepatic inflammation, pancreatic and kidney functions, and circulating lipids. As shown in Fig. 3, the levels of AST, creatinine, and glucose were very similar in all groups of rats. Compared to WT rats, serum ALT levels were 1.7-fold and 2.4-fold higher in female and male SHROB rats, respectively (Fig. 3b).

The amylase index for both male WT and male SHROB rats was higher than the respective females (Fig. 3c). Compared with WT rats, the levels of BUN were greater in both male (~34%) and female (~48%) SHROB rats (Fig. 3d). In 10-week-old rats, there were small but insignificant changes in the levels of creatinine and glucose; these animals have been shown to develop proteinuria and renal disease in later life [11]. Both male and female SHROB rats had hypercholesterolemia compared with WT rats (Fig. 3g). The levels of TGs in circulation in female SHROB rats were ~8-fold higher compared to WT females. We should note however, that serum TGs were only 1.85-fold higher in the SHROB males (Fig. 3h). Compared with their WT littermates, hyperinsulinemia was evident in both male and female SHROB rats, with circulating levels of insulin being 14.1-fold and 11.5-fold higher, respectively (Fig. 3i).

Insulin pathway is differently influenced for female and male SHROB rats
Since both hyperinsulinemia and hepatic steatosis were more pronounced in male SHROB rats, we investigated if insulin signaling pathways were differentially impaired in males and females. It has been documented previously [26] that the skeletal muscle and livers of SHROB rats had lower levels of total and phosphorylated insulin receptor substrate 1 (IRS-1). Consistent with earlier reports, we noted that levels of IRS-1 in the livers of SHROB rats were significantly lower (Fig. 4). IRS-1, a key target of insulin receptor kinase, contains more than 30 potential serine/threonine phosphorylation sites; while phosphorylation of some sites (e.g., Y895, Y1222) is associated with activation of IRS-1, phosphorylation of others (e.g., S307) disrupts

![Fig. 3](image-url) Serum chemistries for 10-week-old female and male WT and SHROB rats. Data are mean ± SEM, n = 5 to 12 for each group. a AST, aspartate aminotransferase. b ALT, alanine aminotransferase. c Amylase. d BUN, blood urea nitrogen. e Creatinine. f Glucose. g Cholesterol. h Triglyceride. i Insulin. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001
IRS-1/insulin receptor interaction [31–33]. As shown in Fig. 4, hepatic extracts of male SHROB rats had higher steady-state levels of IRS phosphorylated at S307, reflecting an impairment of insulin signaling.

IRS-1 phosphorylates and activates PI3 kinase that generates PIP3 and activates the 57-kDa Ser/Thr kinase AKT (also known as protein kinase B, PKB) via phosphorylation at T308. As judged by pAKT (T308) levels in the hepatic extracts of SHROB females (Fig. 4), they elicited greater insulin sensitivity compared with their male counterparts. We should note however, that despite gender-specific differences seen in the proximal steps of insulin signaling pathway, the downstream activation of the mTOR (mechanistic target of rapamycin) signals was apparently elicited in a gender-neutral fashion. Thus, we did not observe significant differences in the constitutive levels of total or
phosphorylated mTOR, p70S6K, and S6K in the liver extracts obtained from male and female SHROB rats (Fig. 4).

Crosstalk between PI3K-AKT/PKB and MAPK signaling is known to be significantly altered during hyperinsulinemia [34]. Therefore, we assessed putative changes in the activation of MAPK pathways and their downstream consequences for hepatic gene expression in female and male SHROB rats (Fig. 5). We discovered that SHROB rats of both genders had higher levels of p-p38MAPK (phosphorylated at T180/Y182) and p-ERK1/2 (phosphorylated at T202/Y204) compared to their respective WT counterparts. In contrast, hepatic extracts of female SHROB rats had higher constitutive levels of activated SAPK/JNK, phosphorylated at T183/Y185 (Fig. 5).

Since the canonical PI3K-AKT/PKB and MAPK signaling pathways culminate in the nucleus by inducing a program of gene expression relegated to de novo lipid synthesis and gluconeogenesis, we quantified expression of a subset of metabolic regulators by western blot analysis, followed by densitometry (Fig. 6). These experiments revealed that the steady-state levels of proteins involved in de novo lipid biosynthesis (pSREBP1, nSREBP1, ACC1, and FASN) were expressed more abundantly in the livers of SHROB rats. We also noted however, that female SHROB rat livers elicited greater expression of pSREBP2, nSREBP2, p-AMPK, and AMPK (Fig. 6). In contrast, the expression of ChREBP (carbohydrate response element-binding protein), a key transcription factor involved in de novo lipid synthesis [35, 36] was more abundantly expressed in the livers of SHROB males. Interestingly, the steady-state levels of total and phosphorylated AMP-activated protein kinase (AMPK) were higher in the livers of SHROB females (Fig. 6).

Quantification of gene expression by qPCR in WT and SHROB rats
To further investigate the putative molecular basis of sexual dimorphism in hepatic lipid metabolism in
SHROB rats, we assessed the mRNA levels of a panel of 45 genes shown previously to be differentially regulated in males and females [37]. As shown in Fig. 7, the expression of Pparg, Ppara, Slc2a4, Atox1, Skp1, and Angptl3 genes was moderately increased in the female SHROB rats; however, these animals elicited much greater expression of Cd36 compared with SHROB males. Moreover, although steady-state levels of mRNAs encoded by Srebf1, Acaca, Scd, Fasn, and Acly were increased in both male and females, and their expression was significantly greater in males; a ~500-fold induction of Pnpla3 expression in SHROB males was particularly notable (Fig. 7).

The four cardinal features of MetS in humans, insulin resistance, visceral adiposity, severe dyslipidemia, and endothelial dysfunction are often associated with systemic inflammation [6]. Therefore, we investigated if expression of canonical pro-inflammatory genes (e.g., Tnf, IL-1b, IL-6, and Ccl2) in the livers of male and female SHROB rats were differentially affected. As judged by the results of qPCR, none of the target genes showed gender-associated differential expression of the livers of WT or SHROB rats (data not shown).

Discussion
Non-alcoholic fatty liver disease (NAFLD) is frequently associated with MetS [38]. The initial stage of NAFLD is hepatic steatosis, which may progress to non-alcoholic steatohepatitis [38] and eventually hepatocellular carcinoma [39]. Both epidemiological and animal studies.
indicate that the prevalence of NAFLD is higher in males [21, 40, 41]. However, the underlying mechanistic basis of sex-specific differences of hepatic steatosis and its clinical consequences are poorly understood.

The SHROB (fa/fak) shows several features of human MetS [6] that include obesity, hyperinsulinemia, hyperlipidemia, and genetically encoded hypertension [23, 24, 26]. Although hormonal and biochemical underpinnings of MetS have been extensively analyzed in SHROB rats, here, we show for the first time that there are gender-specific differences in the development of hepatic steatosis in these animals. Additionally, we show that hyperinsulinemia-induced signaling pathways and a panoply of hepatic genes involved in lipid biosynthesis and metabolism are differentially regulated in male and female SHROB rats.

Consistent with earlier reports, insulin signaling pathways were significantly blunted in SHROB rats, regardless of gender. Nevertheless, SHROB females were significantly more insulin-sensitive. Additionally, we noted

![Fig. 7](image-url)
gender-specific differences in phosphorylation-dependent activation of p38MAPK, ERK1/2, and SAPK/JNK. The MAPK pathway is characterized by a 3-tier sequential activation of MAPK kinase kinase (MKKK), MAPK kinase (MKK), and MAPK. Extracellular stimuli trigger the MKKK and its downstream cascade of kinases via protein-protein interactions, phosphorylation, and subcellular compartmentalization [34]. The MAPK signaling cascades impinge on transcription factors like ELK-1 [42], PPARγ 2 [43], and SREBP [44] that regulate gene networks involved in energy homeostasis. Kotzka et al. have shown that the N-termini of SREBP-1a, SREBP-1c, and SREBP-2 are phosphorylated by ERK, JNK, and p38 MAPK [45–48]. The importance of MAPK-mediated phosphorylation of SREBP-1 in pathophysiology of MetS in humans was bolstered by the finding of a rare allele of SREBP-1, defective in serine 117 phosphorylation by ERK and JNK. Patients carrying this mutation elicited severe combined hypolipidemia [49]. Thus, SREBPs converge at the regulatory nexus of insulin resistance, obesity, and inflammation, all of which are subject to regulation by MAPK [50].

Quantification of expression of 45 genes that may contribute to gender-specific differences in hepatic steatosis [37] revealed a rather complex picture of hepatic lipid metabolism in SHROB rats. Thus, genes encoding Srebf1, Acaca, Sod, Fasn, and Acly were highly induced in the livers of SHROB rats. However, with the exception of Acaca, all were similarly induced in the livers of males and females. In contrast, expression of seven genes (Pparg, Cd36, Slc2a4, Atox1, Angptl3, and Pnpla3) showed a gender-specific bias. The aberrant expression of PPARy [51] is associated with NAFLD [52–54], and liver-specific loss of PPARy is known to markedly attenuate the pathogenesis of NAFLD [55, 56]. The PPARy activates SREBP-1c, a master transcription factor that promotes de novo lipid synthesis [57]. PPARy2 and C/EBPα cooperate to activate transcription of many adipocyte specific genes [58]. We posit that more enhanced expression of PPARy in males versus females is mechanistically involved in differential regulation of hepatic steatosis in SHROB rats. PPARa stimulates β-oxidation of fatty acids; PPARα ligands trigger SCID1 activity which is necessary for VLDL secretion [59].

The livers of male SHROB rats expressed lower levels of the Cd36 gene, consistent with their genetic derivation from Wistar Kyoto (WKY) strain [26, 60]. Cd36 protein belongs to the class B scavenger receptor family [61] and binds to native and oxidized low-density lipoproteins [62] and long-chain fatty acids [63]. The Cd36 receptor promotes fatty acid uptake into muscle and adipose tissues [64–66]. Deficiency of Cd36 in SHR rats, shown to be associated with insulin resistance [67, 68], could be corrected by exogenously expressed Cd36 [69]. Hyperlipidemia and insulin resistance have been reported in Cd36-deficient mice [70, 71] and humans [61]. Expression of Slc2a4 was higher in male SHROB rats putatively causing greater influx of glucose, thus accelerating its flux into the Krebs cycle. Therefore, we posit that enhanced influx of glucose and fatty acids into the livers of male SHROB rats led to more de novo lipid biosynthesis.

All SHROB rats elicited an enhanced expression of Pnpla3, but its ~ 500-fold induction in the livers of male rats was remarkable. Pnpla3 encodes a nonspecific lipid acyl hydrolase that is highly expressed in the liver and adipose tissue [72]. Ninety percent of Pnpla3 in hepatocytes is associated with lipid droplets [73]; the mechanism by which Pnpla3 regulates lipid droplet biogenesis remains controversial [74]. Expression of Pnpla3 is highly induced by carbohydrate feeding and insulin [75]. The promoter of murine Pnpla3 gene contains consensus binding sites for ChREBP and SREBP-1c [76, 77]. Therefore, it is highly likely that enhanced accumulation of lipid droplets in the livers of SHROB males may be a direct result of elevated expression of ChREBP and SREBP-1c that transcriptionally activated the Pnpla3 gene.

The expression of Atox1 and Skp1 mRNA was higher in male SHROB rats than female SHROB rats. Induction of Atox1 and Skp1 has been associated with high levels of TGs in liver and adipose tissue [37]. Skp1a is a component of SCF complex that plays a key role in hepatic lipid accumulation [78]. Hepatic expression of the angiopoietin-like protein 3 (Angptl3) mRNA was also higher in SHROB males. ANGPTL3 is a member of a family of secreted glycoproteins structurally related to angiopoietins that regulates lipid, glucose, and energy metabolism [79–81]. ANGPTL3 is highly expressed in the liver and acts in concert with LXR [80, 82]. The livers of db/db mice expressed high levels of Angptl3 [83] that could be normalized by leptin treatment [84]. Conversely, targeted deletion of Angptl3 leads to lower plasma TG and cholesterol [85]. Inactivating mutations in the ANGPTL3 gene cause familial combined hypolipidemia, a disorder characterized by profound reduction of plasma lipoproteins [86]. Disabling ANGPTL3 with antisense oligonucleotides or antibodies also lowers plasma TG and LDL cholesterol in humans [87].

**Conclusion**

We have corroborated and extended previous observations to conclude that hepatic steatosis in SHROB rats, regardless of their gender, is driven mainly by higher rates of de novo lipogenesis that occur in a setting of conspicuous absence of hyperglycemia [23, 24, 26]. Additionally, our data indicated that female SHROB rats elicited more efficient fatty acid transport (Cd36) and esterification (Pnpla3), and greater insulin sensitivity.
(higher phosphorylation of AKT and AMPK), all of which contributed to less severe steatosis. Differential regulation of AMPK in male and female SHROB rats is of great interest since AMPK is known to improve insulin sensitivity by decreasing de novo lipogenesis as well as enhancing both fatty acid oxidation and mitochondrial integrity [88]. A number of recent studies have suggested that a combination of reduced fatty acid oxidation and enhanced rates of de novo lipogenesis might be mechanistically related to differential pathogenesis of NAFLD in humans [21]. Our tentative conclusion must be further moderated by two major caveats. First, the hepatic steatosis in SHROB rats only partially mimics the hepatic consequences of human MetS in light of the dissimilarities in the biology of leptin in rodents and man, where unequivocal involvement of leptin receptor in hepatic steatosis has yet to be demonstrated. Second, an explanation for an apparent lack of markers of overt inflammation and fibrosis, with concomitant induction of SAPK/JNK, in the livers of SHROB rats is puzzling and must await future investigation.

**Perspectives and significance**

Sex-specific differences in hepatic steatosis, differential regulation of hyperinsulinemia-associated signaling pathways, and canonical genes involved in lipid metabolism in male and female SHROB rats, outlined here, are highly significant. SHROB rats are hypogonadal, caused by the loss of leptin signaling and a consequential reduction in luteinizing hormone-releasing hormone (LHRH) in the hypothalamus [11, 89]. The prevalence of NAFLD is higher in men with hypogonadism as well in post-menopausal women [90]. However, our hypothetical scenario explaining these data (Fig. 8) provides only a glimpse into the mechanisms involved in hepatic steatosis and its modulation by gender. This mechanistic picture will be considerably sharpened by more comprehensive, genome-wide analyses of hepatic gene expression, using “omics” techniques [91]. Finally, a clear-cut relevance of experimental findings in SHROB rats to gender-specific differences in NAFLD in humans remains murky, particularly in the absence of overt inflammation and fibrosis in this model. A recent report showing that pro-inflammatory responses associated with NAFLD pathogenesis could be exacerbated if mice were housed at their body temperature rather than kept in a conventional, ambient temperature housing [92]. Thus, under thermo-neutral conditions, fatty diet-induced hepatic steatosis was exacerbated in a gender-specific manner in several strains of mice. The notion of temperature-mediated modulation of the pathogenesis of NAFLD in SHROB rats needs to be experimentally tested.

---

**Additional file**

**Fig. 8** Hypothetical scheme showing major steps involved in sex-specific differences in the pathogenesis of hepatic steatosis in SHROB rats. Both female and male SHROB rats elicit hyperphagia, hyperinsulinemia, and hyperlipidemia. Activation of hyperinsulinemia-induced signaling pathways leads to induction of genes that regulate de novo lipogenesis. Several genes that control lipid metabolism are highly expressed in male and female SHROB rat livers. Expression of Cd36 and Pnpla3 genes was differentially regulated in female and male SHROB rats, leading to milder and severe hepatic steatosis, respectively.

**Additional file 1:** Figure S1. Genotyping of SHROB rats: A: Design of tera-pair primers to amplify leptin receptor region including the T>A mutation by PCR and the resulting sizes of DNA fragments in WT (248-bp...
Abbreviations
Acaca: Acetyl-CoA carboxylase alpha (also known as Acc1); Acacb: Acetyl-CoA carboxylase beta (also known as Acc2); ACC1: Acetyl-CoA carboxylase; Acly: ATP citrate lyase; AKT: Serine/threonine kinase (also known as protein kinase B, PKB); ALT: Alanine aminotransferase; AMPK: AMP-activated protein kinase; Angptl3: Angiopoietin-like protein 3; ANOVA: Analysis of variance; AST: Aminotransferase; Atox1: Antioxidant 1 copper chaperone; BUN: Blood urea nitrogen; Cd36: Cluster of differentiation 36 (also known as fatty acid translocase); ChREBP: Carbohydrate response-element binding protein; ERK: Extracellular signal-regulated kinase; FASN: Fatty acid synthase; Fas: Fas ligand; H&E: Hematoxylin and eosin; IRS-1: Insulin receptor substrate 1; JNK: c-Jun N-terminal kinase; LHRH: Luteinizing hormone-releasing hormone; MAPK: Mitogen-activated protein kinase; MetS: Metabolic syndrome; MKK: MAPK kinase; MKKK: MAPK kinase kinase; MRI: Magnetic resonance imaging; mTOR: Mechanistic target of rapamycin; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; Naive: Naive T-lymphocyte; NOS1: Nitric oxide synthase 1; PKB: Protein kinase B; PKC: Protein kinase C; PKCα: Protein kinase C alpha; PKCθ: Protein kinase C theta; p70S6K: Ribosomal protein S6 kinase; Pparg: Peroxisome proliferator-activated receptor gamma; pSREBP1: Full-length, precursor sterol regulatory element-binding protein 1; pSREBP2: Full-length, precursor sterol regulatory element-binding protein 2; Ppara: Peroxisome proliferator-activated receptor alpha; Pras: Prasmylathrin; Pnpla3: Patatin-like phospholipase domain containing 3; Prapag: Peroxisome proliferator-activated receptor gamma; Pparq: Peroxisome proliferator-activated receptor gamma; SREBP2: Full-length precursor sterol regulatory element-binding protein 2; mTORC1: Mitogen-activated protein kinase complex 1; mTORC2: Mitogen-activated protein kinase complex 2; OC: Osteocalcin; PPARγ: Peroxisome proliferator-activated receptor gamma; Prl: Prolactin; Pnpla2: Patatin-like phospholipase domain containing 2; Prl: Prolactin; Ppara: Peroxisome proliferator-activated receptor alpha.

Funding
This project was partially funded by the Department of Veterans Affairs Merit Review Grants 1I01BX002409 (RR) and 1I01BX002408 (EAP). MK was supported in part by the Frank Dugan Scholarship from the UTHSC.

Availability of data and materials
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
QD, DB, ME, and RR contributed to the conception and design of the research. QD, MK, and XD analyzed the data. QD, MK, and XD performed the experiments. RR approved the final version of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Tennessee Health Science Center (UTHSC).

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Veterans Affairs Medical Center, 1030 Jefferson Avenue, Memphis, TN 38104, USA. 2Department of Pharmacology, College of Medicine, The University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163, USA. 3Department of Nutritional Sciences, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. 4Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN, USA.

References
1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–607.
2. Aguilar M, Shukut T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313:1973–4.
3. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.
4. Chen H, Chariat O, Tartaglia LA, Woof EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996;84:491–3.
5. Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibl RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996;271:994–6.
6. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231–7.
7. Williams KW, Elmqist JK. From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior. Nat Neurosci. 2012;15:1350–5.
8. Ziauddeen H, Farooqi IS, Fletcher PC. Obesity and the brain: how convincing is the addiction model? Nat Rev Neurosci. 2012;13:279–86.
9. Rodriguez A. Novel molecular aspects of ghrelin and leptin in the control of adipobiology and the cardiovascular system. Obes Facts. 2014;7:82–95.
10. Raghow R. Gut-brain crosstalk regulates craving for fatty food. World J Diabetes. 2017;8:484–8.
11. Koletsky S. Obese spontaneous hypertensive rats—a model for study of atherosclerosis. Exp Mol Pathol. 1973;19:53–60.
12. Yen TT, Shaw WN, Yu PL. Genetics of obesity of Zucker rats and Koletsky rats. Heredity (Edinb). 1977;38:373–7.
13. Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Nakao K, Koletsky RJ. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet. 1996;14:130–1.
14. Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, Nakao K. Molecular cloning of rat leptin receptor isoform complementary DNAs—identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun. 1996;225:75–83.
15. Ishizuka T, Ernsberger P, Liu S, Bedol D, Lehman TM, Koletsky RJ, Friedman JE. Phenotypic consequences of a nonsense mutation in the leptin receptor gene (fa/fa) in obese spontaneously hypertensive Koletsky rats (SHROB). J Nutr. 1998;128:299–306.
16. Koletsky S. Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol. 1975;80:129–42.
17. Koletsky S. Animal model obese hypertensive rat. Am J Pathol. 1975;81:463–6.
18. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanjay AJ, American Gastroenterological A, American Association for the Study of Liver D, American College of G. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1525–69.
19. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.
20. Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6:274–83.
21. Premfalk C, Pavilides M, Banerjee R, McNeil CA, Neubauer S, Karpe F, Hodson L. Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men. J Clin Endocrinol Metab. 2015;100:4425–33.
22. Mauvais-Jarvis F, Clegg DJ, Heveren AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34:309–38.
23. Molinar-Toribio E, Perez-Jimenez J, Ramos-Romero S, Llus L, Sanchez-Martos V, Taltavull N, Romeu M, Pazos M, Mendez L, Miranda A, et al.
Cardiovascular disease-related parameters and oxidative stress in SHROB rats, a model for metabolic syndrome. PLoS One. 2014;9:e104637.

24. Mendez L, Pazoos M, Graf M, Nogues MR, Perez-Jimenez J, Torres JL, Gallardo JM, Medina I. Targets of protein carbonylation in spontaneously hypertensive obese Koelsky rats and healthy Wistar counterparts: a potential role on metabolic disorders. J Proteome. 2014;106:246–59.

25. O'Dea K, Koletsy S. Effect of caloric restriction on basal insulin levels and the in vivo lipogenesis and glycogen synthesis from glucose in the Koelsky obese rat. Metabolism. 1977;26:763–72.

26. Ennserberger P, Koletsy RJ, Friedman JE. Molecular pathology in the obese spontaneous hypertensive Koelsky rat: a model of syndrome X. Ann N Y Acad Sci. 1993;692:272–80.

27. Yellaturo CR, Deng X, Cagen UM, Wilcox HG, Mansbach CM 2nd, Siddiqi SA, Park EA, Raghow R, Elam MB. Insulin enhances post-translational processing of nascent SREBP-1c by promoting its phosphorylation and association with COPI vesicles. J Biol Chem. 2009;284:7518–32.

28. Dong Q, Giorgiannii F, Beranova-Giorgiannii S, Deng X, O'Meally RN, Bridges D, Park EA, Cole RN, Elam MB, Raghow R. Glycogen synthase kinase-3-mediated phosphorylation of serine 73 targets sterol response element binding protein-1c (SREBP-1c) for proteostatic degradation. Biochi Rep. 2015;36:e00284.

29. Mehrem A, Hagberg CE, Muhl L, Eriksson U, Falkiewall A. Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc. 2013;8:1149–54.

30. Lu B, Bridges D, Yang Y, Fisher K, Cheng A, Chang L, Meng ZX, Lin JD, Dovines M, Yu RT, et al. Metabolomic crosstalk: molecular links between glycerol and lipid metabolism in obesity. Diabetes. 2014;63:2935–48.

31. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002;277:15317–23.

32. Greene MM, Sakaua H, Wang L, Alessi DR, Roth RA. Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by serine 312 phosphorylation. J Biol Chem. 2003;278:21099–111.

33. Sun XJ, Crimmings DL, Myers MGJ, Mitalipov MS, White MF. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol. 1993;13:4718–28.

34. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase conservation of a three-kine module from yeast to human. Physiol Rev. 1999;79:143–80.

35. Girion J, Ferre P, Foufelle F. Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu Rev Nutr. 1999;19:71–93.

36. Giordano S, Qiu N, Pintel DJ, Houghton J, Winee R, Cinalli R, Melander A. Leptin-deficient mice improve fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003;111:373–47.

37. Zuo L, Kubo M, Sato N. Liver steatosis and gender in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res. 2014;44:326–76.

38. Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Trends Cardiovasc Med. 2003;13:136–41.

39. Naka Y, Okada K, Yamamoto T, Fujii Y, Fujii H, Murakami Y, Ishizuka Y, Tsuchiya Y, Kanda H, et al. Leptin promotes adipogenesis through MAPK-mediated phosphorylation of PPARgamma. Science. 1996;274: 2100–3.

40. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26:3100–12.

41. Kozula J, Muller-Wieland D, Roth G, Kremer L, Mucke M, Schurmann S, Knebel B, Krone W. Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAPK cascade. J Lipid Res. 2000;41:99–108.

42. Kozula J, Lehr S, Roth G, Avci H, Knebel B, Muller-Wieland D. Insulin-activated Erk-mitogen-activated protein kinases phosphorylate sterol regulatory element-binding protein-2 at serine residues 432 and 455 in vivo. J Biol Chem. 2004;279:22404–11.
Cd36 (fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 1999;21:76–83.
68. Glazier AM, Scott J, Atman TJ. Molecular basis of the Cd36 chromosomal deletion underlying SHR defects in insulin action and fatty acid metabolism. Mamm Genome. 2002;13:108–13.
69. Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kozdova L, Atman TJ, Glazier AM, Ibrahimi A, Abumrad NA. Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet. 2001;27:156–8.
70. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, Silverstein RL. A null mutation in murine Cd36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999;274:19055–62.
71. Haji T, Han XX, Bonen A, Abumrad NA. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in Cd36-null mice. J Clin Invest. 2002;109:1381–9.
72. Fuchs CD, Claudel T, Trauner M. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends Endocrinol Metab. 2014; 25:576–85.
73. He S, McPhear C, Li JZ, Garuti R, Kinch L, Grishin NV, Cohen JC, Hobbs HH. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706–15.
74. Mtsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem. 2018; 293:6958–68.
75. Bruschi FV, Tardelli M, Claudel T, Trauner M. PNPLA3 expression and its impact on the liver: current perspectives. Hepat Med. 2017;9:55–66.
76. Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs HH. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010;107:7892–7.
77. Dubuquoy C, Rebichon C, Lasnier F, Langlois C, Dugail I, Foufelle F, Girard J, Bumol AF, Postic C, Mades L. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors CHREBP and SREBP1c in mouse and human hepatocytes. J Hepatol. 2011;55:145–53.
78. Onoyama I, Suzuki A, Matsumoto A, Tomita K, Katagiri H, Oike Y, Nakayama K, Nakayama K. Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J Clin Invest. 2011;121:342–54.
79. Hato T, Tabata M, Oike Y. The role of angiopeitoin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med. 2000;8:86–14.
80. Mattjessin F, Kersten S. Regulation of triglyceride metabolism by angiopeitoin-like proteins. Biochim Biophys Acta. 2012;1821:782–9.
81. Shimizuwa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, Ueda K, Inaba T, Minekura H, Kohama T, Furukawa H. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277:33742–8.
82. Kaplan R, Zhang T, Hernandez M, Gan FX, Wight SD, Waters MG, Cai TQ. Regulation of the angiopeitoin-like protein 3 gene by LXR. J Lipid Res. 2003; 44:36–43.
83. Inukai T, Takashima T, Saito N, Kurokawa K, Watanabe M, Koishi R, Oka Y, Katayama S. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem Biophys Res Commun. 2004;317:1075–9.
84. Shimamura M, Matsuda M, Ando Y, Koishi R, Yasuo H, Furukawa H, Shimomura I. Leptin and insulin down-regulate angiopeitoin-like protein 3, a plasma triglyceride-increasing factor. Biochem Biophys Res Commun. 2004;322:1080–5.
85. Koster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, Hale J, Li D, Qiu Y, Fraser CC, Yang DD, et al. Transgenic angiopeitoin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology. 2005;146:4943–50.
86. Arca M, Minicozzi L, Maranghi M. The angiopeitoin-like protein 3: A hepatokine with expanding role in metabolism. Curr Opin Lipidol. 2013;24:313–20.
87. Kersten S. Angiopeitoin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13:731–9.
88. Smith RK, Steinberg GR. AMP-activated protein kinase, fatty acid metabolism, and insulin sensitivity. Curr Opin Clin Nutr Metab Care. 2017;20:248–53.
89. Koenen-Rheinhardt E, Kalra SP, Kalra PS. AAV-mediated leptin receptor installation improves energy balance and the reproductive status of obese female Koletsky rats. Peptides. 2005;26:2567–78.
90. Mintzor G, Poulakos P, Sarmati C, Goulis DG. Hypogonadism and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42:145–50.
91. Raghow R. An Omics perspective on cardiomyopathies and heart failure. Trends Mol Med. 2016;22:813–27.
92. Giles DA, Moreno-Fernandez ME, Stankiewicz TE, Grapeuntner S, Cappelletti M, Wu D, Mukherjee R, Chan CC, Lawson MJ, Larquist J, et al. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nat Med. 2017;23:829–38.